1.	AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20060317, NCT00719550
2.	AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20070611, NCT00770848
3.	Panitumumab Combination Study With AMG 102 or AMG 479 in Wild-type KRAS mCRC Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 20060447, NCT00788957
4.	A Phase 1b/2 Trial of AMG 479 or AMG 102 in Combination With Platinum-based Chemotherapy as First-Line Treatment for Extensive Stage Small Cell Lung Cancer Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20060534, NCT00791154
5.	A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20060100, NCT00422019
6.	A Phase II Study to Treat Advanced Malignant Glioma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20050253, NCT00427440
7.	Phase II Study of Rilotumumab in Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Temporarily closed Age: 18 and over Sponsor: NCI Protocol IDs: GOG-0170P, GOG-0170P, NCT01039207